360 related articles for article (PubMed ID: 20842465)
1. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.
Geisberg CA; Sawyer DB
Curr Hypertens Rep; 2010 Dec; 12(6):404-10. PubMed ID: 20842465
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
Harake D; Franco VI; Henkel JM; Miller TL; Lipshultz SE
Future Cardiol; 2012 Jul; 8(4):647-70. PubMed ID: 22871201
[TBL] [Abstract][Full Text] [Related]
5. Molecular and cellular mechanisms of anthracycline cardiotoxicity.
Chen B; Peng X; Pentassuglia L; Lim CC; Sawyer DB
Cardiovasc Toxicol; 2007; 7(2):114-21. PubMed ID: 17652815
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
Yun S; Vincelette ND; Abraham I
Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
[TBL] [Abstract][Full Text] [Related]
7. Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.
Meiners B; Shenoy C; Zordoky BN
Biol Sex Differ; 2018 Aug; 9(1):38. PubMed ID: 30157941
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.
Varghese SS; Eekhoudt CR; Jassal DS
Mol Cell Biochem; 2021 Aug; 476(8):3099-3109. PubMed ID: 33835331
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
10. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
Ky B; Carver JR
Heart Fail Clin; 2011 Jul; 7(3):323-31. PubMed ID: 21749884
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline-associated cardiotoxicity in survivors of childhood cancer.
Trachtenberg BH; Landy DC; Franco VI; Henkel JM; Pearson EJ; Miller TL; Lipshultz SE
Pediatr Cardiol; 2011 Mar; 32(3):342-53. PubMed ID: 21221562
[TBL] [Abstract][Full Text] [Related]
12. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
13. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
14. A historical perspective of anthracycline cardiotoxicity.
Ewer MS; Von Hoff DD; Benjamin RS
Heart Fail Clin; 2011 Jul; 7(3):363-72. PubMed ID: 21749888
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline Chemotherapy and Cardiotoxicity.
McGowan JV; Chung R; Maulik A; Piotrowska I; Walker JM; Yellon DM
Cardiovasc Drugs Ther; 2017 Feb; 31(1):63-75. PubMed ID: 28185035
[TBL] [Abstract][Full Text] [Related]
16. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
Blanter JB; Frishman WH
Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
[TBL] [Abstract][Full Text] [Related]
19. Ranolazine in the prevention of anthracycline cardiotoxicity.
Corradi F; Paolini L; De Caterina R
Pharmacol Res; 2014 Jan; 79():88-102. PubMed ID: 24269342
[TBL] [Abstract][Full Text] [Related]
20. Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations.
Abdel-Rahman O; Alorabi M
Expert Rev Anticancer Ther; 2015; 15(7):829-37. PubMed ID: 26013380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
